Drug intelligence / Profile preview

YBioA4002

Development stage: Unknown
Lead developer: Yerlika Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

YBioA4002 is a biosimilar candidate of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). Developed by Yerlika Biopharma, it is designed to inhibit tumor angiogenesis, thereby suppressing the growth and metastasis of various malignancies. The drug is intended for the treatment of several types of cancer, including colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. As of early 2026, YBioA4002 is in the NDA/BLA stage in Turkey, with validation batches of both the active pharmaceutical ingredient (API) and finished product completed, and a dossier submission that occurred in 2025.

Other names: bevacizumab biosimilar

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on YBioA4002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YBioA4002.

Explore the full profile